Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients

PURPOSE: This phase I trial aimed to assess the safety and determine the recommended Phase II dose (RP2D) of Cidofovir combined with chemoradiotherapy in patients with stage IB2-IVA cervical cancer. EXPERIMENTAL DESIGN: Incremental doses (1, 2.5, 5 and 6.5 mg/kg) of IV Cidofovir were administered we...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Deutsch, Eric, Haie-Meder, Christine, Bayar, Mohamed Amine, Mondini, Michele, Laporte, Mélanie, Mazeron, Renaud, Adam, Julien, Varga, Andrea, Vassal, Gilles, Magné, Nicolas, Chargari, Cyrus, Lanoy, Emilie, Pautier, Patricia, Levy, Antonin, Soria, Jean-Charles
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2016
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5041925/
https://ncbi.nlm.nih.gov/pubmed/27016411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8224
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires